| FY 2005 (No.212-223) |
Japanese
version
issued
on |
No. |
Table of contents |
Posted
on |
PDF |
| March 23, 2006 |
223 |
- 1.
- Important Safety Information
- (1)
- Selegiline Hydrochloride
- 2.
- Revision of PRECAUTIONS (No. 174)
Lornoxicam (and 3 others)
- 3.
- List of products subject to Early Post-marketing Phase Vigilance
|
|
(Full text) |
| February 23, 2006 |
222 |
- 1.
- Drug Guide for Patients
- 2.
- Revision of PRECAUTIONS (No. 173)
Amoxapine (and 16 others)
- 3.
- List of products subject to Early Post-marketing Phase Vigilance
|
|
(Full text) |
| January 26, 2006 |
221 |
- 1.
- Proper use of theophylline in childhood asthma
- 2.
- Impact of X-ray CT apparatus etc. on implantable cardiac pacemaker etc.
- 3.
- Revision of PRECAUTIONS (No. 172)
- (1)
- Ibuprofen (and 13 others)
- (2)
- Electrosurgical unit (ESU) used in for radiofrequency ablation (RFA)
- 4.
- List of products subject to Early Post-marketing Phase Vigilance
|
|
(Full text) |
| December 22, 2005 |
220 |
- 1.
- Important Safety Information
- (1)
- Amiodarone Hydrochloride
- (2)
- Carboplatin
- (3)
- Sevoflurane
- (4)
- Whole Human Blood, Blood for Exchange Transfusion, Fresh-Frozen Human Plasma, Concentrated Human Blood Platelet, Concentrated Human Red Blood Cell, Concentrated Frozen-Thawed Human Red Blood Cells, Washed Human Red Blood Cells, Leukocyte Poor Red Blood Cells
- (5)
- Phenytoin, Phenytoin Sodium, Phenytoin/Phenobarbital,
Phenytoin/Phenobarbital/Caffeine and Sodium Benzoate
- 2.
- Revision of PRECAUTIONS (No. 171)
Zopiclone and (12 others)
- 3.
- List of products subject to Early Post-marketing Phase Vigilance
|
|
(Full text) |
| November 24, 2005 |
219 |
- 1.
- Important Safety Information
- (1)
- Barium Sulfate (excepting preparation for CT)
- (2)
- Fludarabine Phosphate
- 2.
- Revision of PRECAUTIONS (No. 170)
Bepridil Hydrochloride (and 11 others)
- 3.
- List of products subject to Early Post-marketing Phase Vigilance
(Reference Material)
-
- Future Perspective of pharmacogenomics
|
|
(Full text) |
| October 27, 2005 |
218 |
- 1.
- Result of post-marketing safety measures for ticlopidine hydrochloride products with Cypher Stent
- 2.
- Serious skin disorders induced by drugs
- 3.
- List of products subject to Early Post-marketing Phase Vigilance
|
|
(Full text) |
| September 29, 2005 |
217 |
- 1.
- Reports etc. on the adverse reactions of the influenza vaccines in FY2004
- 2.
- Important Safety Information
- (1)
- Zedoary Powder and Japanese Tangle Powder Preparation
- 3.
- Revision of PRECAUTIONS (No. 169)
Paroxetine Hydrochloride Hydrate (and 9 others)
- 4.
- List of products subject to Early Post-marketing Phase Vigilance
|
|
(Full text) |
| August 25, 2005
|
216 |
- 1.
- Serious health hazards in the use of bone cement
- 2.
- Effects on implantable medical devices (cardiac pacemakers and cardioverter defibrillators) by new system mobile phone terminals and RFID device
- 3.
- Important Safety Information
- (1)
- Sodium Valproate
- (2)
- Pranoprofen (oral dosage form)
- (3)
- Hochuekkito
- 4.
- Revision of PRECAUTIONS (No.168)
Carbamazepine (and 12 others)
- 5.
- List of products subject to Early Post-marketing Phase Vigilance
|
|
(Full text) |
| July 27, 2005
|
215 |
- 1.
- Important Safety Information
- (1)
- Ethionamide
- (2)
- Etodolac
- (3)
- Gemcitabine Hydrochloride
- (4)
- Omeprazole, Omeprazole Sodium
- 2.
- Revision of PRECAUTIONS (No.167)
Tiaprofenic Acid (and 17 others)
- 3.
- List of products subject to Early Post-marketing Phase Vigilance
|
|
(Full text) |
| June 23, 2005
|
214 |
- 1.
- Important Safety Information
- (1)
- Alprostadil, Alprostadil Alfadex (20 ug injectable dosage form)
- (2)
- Donepezil Hydrochloride
- (3)
- Leuprorelin Acetate
- (4)
- Lopinavir/Ritonavir
- 2.
- Revision of PRECAUTIONS (No. 166)
Cabergoline (and 15 others)
- 3.
- List of products subject to Early Post-marketing Phase Vigilance
|
|
(Full text) |
| May 26, 2005
|
213 |
- 1.
- Impact of X-ray CT apparatus on implantable cardiac pacemaker (Medtronic InSync 8040)
- 2.
- Important Safety Information
- (1)
- Candesartan Cilexetil, Telmisartan, Valsartan, Losartan Potassium
- (2)
- Ceftriaxone Sodium
- (3)
- Adsorbed Diphtheria-Purified Pertussisi-Tetanus Combined Vaccine
- (4)
- Torasemide
- (5)
- Japanese Encephalitis Vaccine
- 3.
- Revision of PRECAUTIONS (No. 165)
Fradiomycin Sulfate/
Methylprednisolone Betamethasone Sodium Phosphate/Fradiomycin Sulfate
(ophthalmic ointment) (and 19 others)
- 4.
- List of products subject to Early Post-marketing Phase Vigilance
|
|
(Full text) |
| April 27, 2005
|
212 |
- 1.
- Results of investigation by the Gefitinib review meeting
- 2.
- Overview of the notifications for self-inspection etc.
issued from April 2004 to February 2005
- 3.
- Request for cooperation in Early Post-marketing Phase Vigilance
|
|
(Full text) |
